DURAGESIC-12 Drug Patent Profile

Which patents cover Duragesic-12, and what generic alternatives are available?

Duragesic-12 is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in DURAGESIC-12 is fentanyl. There are thirty-one drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fentanyl profile page.

Summary for DURAGESIC-12

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DURAGESIC-12

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	DURAGESIC-12	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	019813-005	Feb 4, 2005		DISCN	Yes	No

International Patents for DURAGESIC-12

See the table below for patents covering DURAGESIC-12 around the world.

Country	Patent Number	Title	Estimated Expiration
France	2567761	DISPOSITIF D'APPORT TRANSDERMIQUE POUR L'ADMINISTRATION DE FENTANYL
Hong Kong	8191	TRANSDERMAL ADMINISTRATION OF FENTANYL AND DEVICE THEREFOR
Germany	3546869	Transdermales Abgabesystem zur Verabreichung von Fentanyl
Spain	545366

Supplementary Protection Certificates for DURAGESIC-12

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1635783	122014000024	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
1769785	C300522	Netherlands		PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
0975367	122011000009	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
0901368	C300523	Netherlands		PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006

Duragesic-12 (Fentanyl Transdermal Patch): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Duragesic-12 (fentanyl transdermal patch) is a potent opioid analgesic indicated for managing chronic pain in opioid-tolerant patients. As a product within the opioid analgesics segment, its market positioning faces unique challenges and opportunities driven by regulatory, societal, and technological factors. This analysis explores the investment prospects, market dynamics, and financial forecasts for Duragesic-12, emphasizing trends, competitive landscape, regulatory environment, and pricing strategies.

---

What Is the Current Market Position of Duragesic-12?

Parameter	Details/Range
Therapeutic Area	Chronic pain management
Formulation	Transdermal patch (12 mcg/hr dose)
Manufacturer	Janssen Pharmaceuticals (Johnson & Johnson)
Market Approval Date	Approved by FDA in 1991
Patent Expiry	Patent protections largely expired; generic availability since ~2012
Pricing (approximate)	~$8-$15 per patch, depending on formulation and region

---

Market Dynamics

1. Regulatory Environment

Opioid Regulation and Abuse Prevention:

• Heightened regulations globally aim to curb opioid misuse, impacting prescription volumes.
• In the US, CDC guidelines (2016) and DEA scheduling revisions have influenced prescribing habits.
• Manufacturers are required to implement Risk Evaluation and Mitigation Strategies (REMS)—which include mandatory training and patient safeguards.

Impact on Duragesic-12:

• Stricter prescribing and distribution controls limit market expansion.
• Off-label use diminishes due to regulatory scrutiny, weighing down revenue potential.

2. Market Size and Segmentation

Global Market Estimates (2022):	Region	Market Size (USD millions)	CAGR (2022–2027)	Notes
North America	~$2,500	3.5%	Largest market, mature but declining due to regulation
Europe	~$900	2.8%	Strong regulatory oversight, high penetration
Asia-Pacific	~$300	7.0%	Emerging market, growing opioid acceptance
Rest of World	~$200	4.5%	Variability in regulation and access

Key Market Drivers:

• Increased prevalence of chronic pain, especially with aging populations.
• Growing acceptance of transdermal technology as convenient and non-invasive.

3. Competitive Landscape

Competitors	Product	Formulation	Market Share (Est.)	Strengths
M药 (Innovator)	Duragesic-12	Transdermal patch	~60% (pre-COVID)	Brand recognition, established efficacy
Generic Manufacturers	Multiple generics	Transdermal patches	~40%	Cost competitiveness, wider access

Emerging Competitors:

• Non-opioid analgesics, including nerve growth factor inhibitors and gabapentinoids, start to dilute opioid market share.
• Novel delivery systems (e.g., implantables, buccal films) threaten transdermal patches.

4. Societal and Socioeconomic Factors

• Increasing awareness of opioid epidemic consequences impacts prescribing behaviors globally.
• Insurance reimbursement policies influence patient access and physician prescription patterns.
• Growing preference for multimodal pain management shifts demand away from high-dose opioids.

---

Financial Trajectory and Investment Outlook

1. Revenue Trends and Forecasts

Parameter	2022 (Estimated)	2027 (Forecast)	CAGR (2022–2027)	Notes
Revenue (USD millions)	~$100	~$75	-3.8%	Declining trend considering market saturation and regulation
Volume (units)	~10 million patches	~8 million patches	-4%	Due to stricter prescribing

2. Premium vs. Generic Market Impact

• Original branded Duragesic-12 commanded premiums (~20-30%) over generics.
• Patent expiration (~2012) led to an influx of generics reducing pricing power.
• Current margins are under pressure, with generic competition constraining revenue and profit.

3. Regulatory and Litigation Factors

• Increased litigation related to opioid misuse hampers market confidence and sales.
• Enhanced REMS and abuse-deterrent formulations may incur additional R&D costs but are necessary for regulatory compliance.

4. Investment Risks and Opportunities

Risk Factors	Implication
Regulatory Stringency	Reduced prescriptions and market access, lower revenues
Litigation & Liability	Increased costs and potential liabilities impacting profitability
Market Saturation	Difficulty capturing new customers, reliance on existing patient base
Alternative Technologies	Threat of novel pain management platforms diminishing market share

Opportunity Factors	Implication
Aging Population Growth	Potential for increased demand in arthritis, cancer pain, etc.
Geographic Expansion (APAC)	Emerging markets with less regulation present growth prospects
Formulation Innovations	Next-generation patches with abuse-deterrent or longer-acting features

---

Comparison of Key Commercial Strategies

Strategy	Description	Potential Impact
Price Optimization	Adjust pricing to balance access and profit margins	Maintains competitiveness but risks regulatory scrutiny
Market Diversification	Expansion into new geographies or indications	Growth potential in emerging markets
Innovation & Line Extensions	Development of abuse-deterrent formulations or combo products	Differentiation, potential premium pricing
Strategic Partnerships	Licensing, co-marketing agreements with generics or biotech firms	Expands market reach and reduces R&D costs

---

Regulatory and Policy Outlook

• United States: Continued tightening of opioid prescribing, with CDC and DEA oversight. Increased focus on abuse-deterrent formulations, with FDA emphasizing flexible risk management.
• Europe: Moderate regulation; emphasis on prescription monitoring.
• Asia-Pacific: Growing acceptance, though regulatory pathways vary per country.

Implications for Investment: Companies must navigate evolving policies, balancing access with compliance to sustain revenue.

---

Key Takeaways

• Market Maturity: Duragesic-12 faces declining growth due to patent expiry, generic competition, and regulatory restrictions, with a projected CAGR of -3.8% through 2027 in revenue terms.
• Regulatory Environment: Heightened regulation and societal concerns over opioids necessitate strategic innovation, especially abuse-deterrent technologies.
• Emerging Opportunities: Aging populations and unmet needs in certain geographies, such as Asia-Pacific, offer growth avenues.
• Competitive Positioning: Sustaining profitability hinges on product differentiation, including formulations with improved safety profiles.
• Investment Consideration: Given current market constraints, a focus on diversification, innovations, and regulatory navigation is essential for future value capturing.

---

FAQs

1. How does regulatory scrutiny affect Duragesic-12’s sales projections?

Regulatory scrutiny leads to stricter prescribing practices, increased oversight, and tighter controls to prevent misuse, which collectively reduce prescription volumes and limit revenue growth.

2. Are there any new formulations of Duragesic-12 in development?

No publicly disclosed reformulations specific to Duragesic-12 are imminent, but companies are investing in abuse-deterrent formulations for similar opioids, which could influence the product’s future marketability.

3. What is the potential impact of alternative pain management therapies on Duragesic-12?

Emerging therapies, including non-opioid painkillers and neuromodulation devices, threaten to reduce demand for traditional opioids, including Duragesic-12.

4. How does the pricing of Duragesic-12 compare across regions?

Pricing varies significantly, with higher premiums in the US (~$10-$15 per patch) versus lower prices in regions with greater generic penetration and pricing controls.

5. What are the key legal risks associated with Duragesic-12?

Legal risks include lawsuits related to opioid misuse, addiction, and adverse events, which may result in monetary damages, regulatory penalties, and reputational harm.

---

References

1. U.S. Food and Drug Administration (FDA). (2021). Fentanyl Transdermal System (Duragesic): Labeling and Regulatory Status.
2. IQVIA. (2022). Global Pain Management Market Analysis.
3. CDC. (2016). Guideline for Prescribing Opioids for Chronic Pain.
4. European Medicines Agency (EMA). (2021). Opioid Analgesics Market Overview.
5. Johnson & Johnson. (2022). Annual Report and Market Strategies for Duragesic.

---